AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17615477 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 15282117 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake
Number of subjects: 0
Study 15282117 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 12642692 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide monotherapy (200 to 1,200 mg/day)
Number of subjects: 63
Study 9457020 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (combination)
Number of subjects: 166
Study 9457020 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliance (modified bionator)
Number of subjects: 166
Study 9457020 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 166
Study 9457020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study 10172461 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled corticosteroid)
Number of subjects: 0
Study 10172461 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (once-daily administration in dry powder form via Turbuhaler)
Number of subjects: 0
Study 10172461 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 1761121 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (low-dose continuous administration)
Number of subjects: 234
Study 1761121 — intervention group
Group type: COMPARATOR
Intervention: No Heparin
Number of subjects: 234
Study 6813959 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (25 mg, two tablets)
Number of subjects: 12
Study 6813959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets)
Number of subjects: 12
Study 31350027 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR
Number of subjects: 2028
Study 31350027 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2028
Study 30756339 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost inhalation (20 µg)
Number of subjects: 253
Study 30756339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 27664095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IGB)
Number of subjects: 115
Study 27664095 — intervention group
Group type: COMPARATOR
Intervention: Standard Medical Care (SMC)
Number of subjects: 115
Study 25660925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor therapy
Number of subjects: 18624
Study 25660925 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel therapy
Number of subjects: 18624
Study 24326597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 185
Study 24326597 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 185
Study 22166801 — intervention group
Group type: EXPERIMENTAL
Intervention: Grilled meat
Number of subjects: 1008
Study 22166801 — intervention group
Group type: EXPERIMENTAL
Intervention: Well or very well‐done meat
Number of subjects: 1008
Study 22166801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐amino‐1‐methyl‐6‐phenyl‐imidazo[4,5‐b]pyridine (PhIP)
Number of subjects: 1008
Study 22166801 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzo[a]pyrene
Number of subjects: 1008
Study 22166801 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mutagenic activity
Number of subjects: 1008
Study 22166801 — intervention group
Group type: EXPERIMENTAL
Intervention: Total iron (diet and supplements)
Number of subjects: 1008
Study 22166801 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron from supplements
Number of subjects: 1008
Study 20467605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid synthetic resorbable barriers (Inion)
Number of subjects: 10
Study 20467605 — intervention group
Group type: COMPARATOR
Intervention: Granular anorganic bovine bone (Bio‐Oss)
Number of subjects: 10
Study 17721018 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP administration
Number of subjects: 124
Study 17721018 — intervention group
Group type: COMPARATOR
Intervention: non-hANP group
Number of subjects: 124
Study 15206993 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice 200 ml
Number of subjects: 10
Study 15206993 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 12375798 — intervention group
Group type: EXPERIMENTAL
Intervention: Topoisomerase I inhibitors in nonplatinum combinations
Number of subjects: 0
Study 12375798 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based combinations
Number of subjects: 0
Study 9661000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 12
Study 9661000 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin 800 mg
Number of subjects: 12
Study 8619366 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.05 IU/kg/day
Number of subjects: 40
Study 8619366 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.10 IU/kg/day
Number of subjects: 40
Study 8619366 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.20 IU/kg/day
Number of subjects: 40
Study 8619366 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 40
Study 8619366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2527054 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin plus bath PUVA (trimethylpsoralen bath + UVA)
Number of subjects: 34
Study 2527054 — intervention group
Group type: COMPARATOR
Intervention: Etretinate plus bath PUVA
Number of subjects: 34
Study 344042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocryptine (average daily dose 71 mg)
Number of subjects: 23
Study 344042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocryptine
Number of subjects: 23
Study 31278091 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and implementation of essential interventions for CVD prevention in primary healthcare (n=10)
Number of subjects: 20
Study 31278091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=10)
Number of subjects: 20
Study 28118281 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 106
Study 28118281 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone addition
Number of subjects: 106
Study 26387012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment for neonatal encephalopathy
Number of subjects: 124
Study 23279630 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and physical exercise programme
Number of subjects: 56
Study 23279630 — intervention group
Group type: COMPARATOR
Intervention: Regular activities in the centre (Control)
Number of subjects: 56
Study 21864816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 3602
Study 21864816 — intervention group
Group type: COMPARATOR
Intervention: UFH plus GPI
Number of subjects: 3602
Study 21864816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 21864816 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 3602
Study 21864816 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 3602
Study 21864816 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 3602
Study 18988892 — intervention group
Group type: EXPERIMENTAL
Intervention: LY518674 (100 microg)
Number of subjects: 28
Study 18988892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17943569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 284
Study 17943569 — intervention group
Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 284
Study 15507932 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 46
Study 11794965 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 11794965 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 0
Study 9142061 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent live attenuated (RA27/3 strain) rubella vaccine
Number of subjects: 546
Study 9142061 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 546
Study 7959143 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased fetal movement (study group)
Number of subjects: 200
Study 7959143 — intervention group
Group type: COMPARATOR
Intervention: Normal fetal movement (control group)
Number of subjects: 200
Study 3664944 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative doxorubicin instillation
Number of subjects: 51
Study 3664944 — intervention group
Group type: COMPARATOR
Intervention: TUR alone (Control)
Number of subjects: 51
Study 31217148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 70
Study 31217148 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stents (EES)
Number of subjects: 70
Study 29164723 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 30
Study 29164723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27264217 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (Resolute Integrity) or everolimus-eluting stents (Promus Element)
Number of subjects: 798
Study 24256334 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus honey mouthwashes
Number of subjects: 120
Study 24256334 — intervention group
Group type: COMPARATOR
Intervention: Lemon candy (standard treatment)
Number of subjects: 120
Study 23919857 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V/DNG (oestradiol valerate/dienogest) administered in a dynamic dosing regimen (26/2 regimen)
Number of subjects: 441
Study 23919857 — intervention group
Group type: COMPARATOR
Intervention: EE/LNG (ethinyloestradiol/levonorgestrel) in a monophasic regimen (21/7 regimen)
Number of subjects: 441
Study 23919857 — intervention group
Group type: EXPERIMENTAL
Intervention: E2V/DNG
Number of subjects: 441
Study 21534684 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized experiment
Number of subjects: 588
Study 21534684 — intervention group
Group type: COMPARATOR
Intervention: Regression discontinuity design
Number of subjects: 588
Study 18978610 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sled towing with approximately 10% body mass (BM)
Number of subjects: 10
Study 18978610 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sled towing with approximately 20% body mass (BM)
Number of subjects: 10
Study 18978610 — intervention group
Group type: COMPARATOR
Intervention: Unresisted sprints
Number of subjects: 10
Study 16263828 — intervention group
Group type: COMPARATOR
Intervention: 0.24 mg/kg x wk GH
Number of subjects: 0
Study 16263828 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.37 mg/kg x wk GH
Number of subjects: 0
Study 12748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist led intervention to improve drug compliance
Number of subjects: 152
Study 12748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 152
Study 12748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on medical history, weight, presence of oedema, and lower blood pressure
Number of subjects: 152
Study 12748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with addition of beta blockers
Number of subjects: 152
Study 12748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with addition of NYHA class
Number of subjects: 152
Study 12748212 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with data on quality of life
Number of subjects: 152
Study 10808985 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer intervention
Number of subjects: 209
Study 10808985 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard teacher-led intervention
Number of subjects: 209
Study 10808985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study 10808985 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up survey
Number of subjects: 209
Study 8820427 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 20
Study 8820427 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg) + Quinidine (100 mg daily)
Number of subjects: 20
Study 1602035 — intervention group
Group type: EXPERIMENTAL
Intervention: Meswak
Number of subjects: 0
Study 1602035 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 0
Study 3893701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-codeine phosphate combination
Number of subjects: 127
Study 3893701 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac
Number of subjects: 127
Study 3893701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 31320282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 31320282 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study 29727366 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed music intervention
Number of subjects: 0
Study 29727366 — intervention group
Group type: COMPARATOR
Intervention: Usual ICU care
Number of subjects: 0
Study 27559840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-dose (AD) group: increase of ribavirin dose if D0AUC0‐4h <1755 mcg·h·L
Number of subjects: 221
Study 27559840 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose (FD) group: standard of care with peginterferon‐α2a 180 mcg·wk and weight‐based ribavirin 1000‐1200 mg/d during 48 weeks
Number of subjects: 221
Study 27559840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-dose (AD) group
Number of subjects: 221
Study 27559840 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose (FD) group
Number of subjects: 221
Study 25041111 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiPen
Number of subjects: 100
Study 25041111 — intervention group
Group type: COMPARATOR
Intervention: Anapen
Number of subjects: 100
Study 22909077 — intervention group
Group type: COMPARATOR
Intervention: Control group without pretreatment sutures (61 cases)
Number of subjects: 302
Study 22909077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic/steroid-coated sutures (200 cases)
Number of subjects: 302
Study 22909077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic-soaked and antibiotic/steroid-coated sutures (141 cases)
Number of subjects: 302
Study 20606677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gallon of polyethylene glycol (PEG) in the morning of the colonoscopy
Number of subjects: 136
Study 20606677 — intervention group
Group type: COMPARATOR
Intervention: 1 gallon of polyethylene glycol (PEG) in the evening before the colonoscopy
Number of subjects: 136
Study 20180666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use diagnosis in PS group
Number of subjects: 515
Study 20180666 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol or opioid use diagnosis in PS group
Number of subjects: 515
Study 20180666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use diagnosis in MM group
Number of subjects: 515
Study 20180666 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use diagnosis in MM group
Number of subjects: 515
Study 20180666 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate use diagnosis in MM group
Number of subjects: 515
Study 20180666 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance using days in both samples
Number of subjects: 515
Study 16130646 — intervention group
Group type: COMPARATOR
Intervention: Normal feet
Number of subjects: 230
Study 16130646 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat feet
Number of subjects: 230
Study 16130646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavus feet
Number of subjects: 230
Study 11906805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (street outreach, cognitive behavioral groups, individual counseling)
Number of subjects: 175
Study 11906805 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 175
Study 11906805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (attended 0-1 cognitive behavioral group sessions)
Number of subjects: 175
Study 9914571 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily during the luteal phase
Number of subjects: 100
Study 9914571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7501348 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drains inserted along the pelvic sidewalls
Number of subjects: 100
Study 7501348 — intervention group
Group type: COMPARATOR
Intervention: No drains inserted
Number of subjects: 100
Study 7501348 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drains
Number of subjects: 100
Study 7501348 — intervention group
Group type: COMPARATOR
Intervention: No drains
Number of subjects: 100
Study 2102130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40-80 mg/day, oral therapy)
Number of subjects: 55
Study 2102130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg, sublingual; 10 mg, intravenous)
Number of subjects: 55
Study 2102130 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 55
Study 2102130 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 55
Study 490345 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stimuli at three different maximal levels applied in randomized order, with 12 sec heat pulses starting from a base line temperature of 43.0-43.5 degrees C.
Number of subjects: 8
Study 490345 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject's ratings on a six-point scale from 'just noticeable' to 'very hot, painful'.
Number of subjects: 8
Study 490345 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated spike discharges from the C fibres.
Number of subjects: 8
Study 30579447 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity simulation training with tablet-paired physical endovascular tool navigation (group S)
Number of subjects: 50
Study 30579447 — intervention group
Group type: COMPARATOR
Intervention: Conventional learning through a video podcast (group V)
Number of subjects: 50
Study 30579447 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity simulation training with tablet-paired touch-gesture navigation (group A)
Number of subjects: 50
Study 28768251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 119
Study 28768251 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 119
Study 28768251 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 119
Study 25652112 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cells delivered onto a β‐tricalcium phosphate scaffold
Number of subjects: 30
Study 25652112 — intervention group
Group type: COMPARATOR
Intervention: Scaffold alone
Number of subjects: 30
Study 22556207 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 58
Study 22556207 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 58
Study 21733417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg orally twice per day for 10 days
Number of subjects: 90
Study 21733417 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg orally three times per day for 10 days
Number of subjects: 90
Study 21733417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 90
Study 19459518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower uterine compression
Number of subjects: 64
Study 19459518 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 64
Study 16843633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 60
Study 16843633 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 60
Study 15319045 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-care telemedicine
Number of subjects: 302
Study 15319045 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for refusal
Number of subjects: 302
Study 15319045 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility criteria
Number of subjects: 302
Study 11843761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux group (dialyzer F6, low-flux polysuphone)
Number of subjects: 72
Study 11843761 — intervention group
Group type: COMPARATOR
Intervention: High-flux group (dialyzer Filtral 12, sulphonated high-flux polyacrylonitrile)
Number of subjects: 72
Study 9509447 — intervention group
Group type: EXPERIMENTAL
Intervention: OL HDF
Number of subjects: 13
Study 7982769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline (levels 9.5 +/- 1 mg/l)
Number of subjects: 12
Study 7982769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2908286 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets
Number of subjects: 0
Study 2908286 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated nets
Number of subjects: 0
Study 15848545 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus (SRL) + cyclosporine (CsA)
Number of subjects: 81
Study 31990581 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptide (CP) supplementation (10 g/day for 12 weeks)
Number of subjects: 167
Study 31990581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 31547517 — intervention group
Group type: EXPERIMENTAL
Intervention: NAS advertising condition
Number of subjects: 1128
Study 31547517 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1128
Study 27598707 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week magazine-based discussion group program, Fit Minded College Edition, with education on physical activity, self-worth, and nutrition.
Number of subjects: 37
Study 27598707 — intervention group
Group type: COMPARATOR
Intervention: Control group received magazines but did not attend meetings or access the website.
Number of subjects: 37